Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
Source: Motley Fool
2026-02-16 03:58:10 ET
On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics (NASDAQ:PTGX) , exercised his stock options and immediately sold 20,000 shares, generating a transaction value of approximately $1.7 million, according to a SEC Form 4 filing .
Transaction value based on SEC Form 4 weighted average purchase price ($83.68); post-transaction value based on Feb. 6, 2026 market close ($83.68).
Protagonist Therapeutics Inc.
NASDAQ: PTGX
PTGX Trading
-0.31% G/L:
$91.345 Last:
235,837 Volume:
$89.96 Open:
PTGX Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 25, 2026 05:15:00 pm
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026 04:05:00 pm
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026 03:48:39 pm
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
PTGX Stock Data
$5,268,820,330
53,263,347
0.64%
112
N/A
Biotechnology & Life Sciences
Healthcare
US
Newark
